Table 1.
Participant characteristics
| Number (%) or Median (IQR) | Total (N=2544, 100%) | No VF (N=2100, 82.5%) | VF (N=444, 17.5%) | |||
|---|---|---|---|---|---|---|
| Frequency or Median | Percentage or IQR | Frequency or Median | Percentage or IQR | Frequency or Median | Percentage or IQR | |
| Age at ART initiation | 39 | 32, 47 | 40 | 33, 48 | 37 | 30. 44 |
| <=30 | 449 | 17.7 | 338 | 16.1 | 111 | 25.0 |
| 31–40 | 907 | 35.7 | 739 | 35.2 | 168 | 37.8 |
| 41–50 | 717 | 28.2 | 598 | 28.5 | 119 | 26.8 |
| >50 | 471 | 18.5 | 425 | 20.2 | 46 | 10.4 |
| Sex | ||||||
| Male | 2,257 | 88.7 | 1,857 | 88.4 | 400 | 90.1 |
| Female | 287 | 11.3 | 243 | 11.6 | 44 | 9.9 |
| Country of birth | ||||||
| Australia & New Zealand | 1,532 | 60.2 | 1,245 | 59.3 | 287 | 64.6 |
| Overseas | 729 | 28.7 | 619 | 29.5 | 110 | 24.8 |
| Unknown | 283 | 11.1 | 236 | 11.2 | 47 | 10.6 |
| HIV mode of acquisition | ||||||
| MSM | 1,808 | 71.1 | 1,500 | 71.4 | 308 | 69.4 |
| Injecting drug use | 134 | 5.3 | 96 | 4.6 | 38 | 8.6 |
| Heterosexual | 516 | 20.3 | 435 | 20.7 | 81 | 18.2 |
| Other/Unknown | 86 | 3.4 | 69 | 3.3 | 17 | 3.8 |
| CD4 at ART initiation, cells/mm 3 | 320 | 200, 489 | 320 | 203, 490 | 290 | 168, 451 |
| <=200 | 497 | 19.5 | 392 | 18.7 | 105 | 23.7 |
| 201–350 | 564 | 22.2 | 480 | 22.9 | 84 | 18.9 |
| 351–500 | 402 | 15.8 | 349 | 16.6 | 53 | 11.9 |
| 500+ | 433 | 17.0 | 366 | 17.4 | 67 | 15.1 |
| Missing | 648 | 25.5 | 513 | 24.4 | 135 | 30.4 |
| HIV RNA at ART initiation, copies/mL | ||||||
| <=100,000 | 1,183 | 46.5 | 994 | 47.3 | 189 | 42.6 |
| >100,000 | 564 | 22.2 | 449 | 21.4 | 115 | 25.9 |
| Missing | 797 | 31.3 | 657 | 31.3 | 140 | 31.5 |
| Treatment interruption duration | ||||||
| No interruption | 1,568 | 61.6 | 1,420 | 67.6 | 148 | 33.3 |
| 1-<14 days | 267 | 10.5 | 238 | 11.3 | 29 | 6.5 |
| 14 days – 3 months | 128 | 5.0 | 101 | 4.8 | 27 | 6.1 |
| 3 months – 6 months | 62 | 2.4 | 33 | 1.6 | 29 | 6.5 |
| > 6 months | 519 | 20.4 | 308 | 14.7 | 211 | 47.5 |
| HBV surface antigen positivity | ||||||
| Negative | 2,055 | 80.8 | 1,676 | 79.8 | 379 | 85.4 |
| Positive | 80 | 3.1 | 60 | 2.9 | 20 | 4.5 |
| Unknown | 409 | 16.1 | 364 | 17.3 | 45 | 10.1 |
| HCV antibody positivity | ||||||
| Negative | 2,087 | 82.0 | 1,732 | 82.5 | 355 | 80.0 |
| Positive | 215 | 8.5 | 165 | 7.9 | 50 | 11.3 |
| Unknown | 242 | 9.5 | 203 | 9.7 | 39 | 8.8 |
| Number of VL measurement, median (IQR) | 14 | (8–23) | 13 | (7–22) | 18 | (10–26) |
| ART type commenced | ||||||
| NRTI+NNRTI | 1,251 | 49.2 | 1,058 | 50.4 | 193 | 43.5 |
| NRTI+PI | 691 | 27.2 | 522 | 24.9 | 169 | 38.1 |
| NRTI+INSTI | 436 | 17.1 | 396 | 18.9 | 40 | 9.0 |
| Other | 166 | 6.5 | 124 | 5.9 | 42 | 9.5 |
| Year of ART initiation | ||||||
| <=2005 | 955 | 37.5 | 733 | 34.9 | 222 | 50.0 |
| 2006–2010 | 696 | 27.4 | 567 | 27.0 | 129 | 29.1 |
| 2011–2015 | 701 | 27.6 | 619 | 29.5 | 82 | 18.5 |
| 2016–2022 | 192 | 7.6 | 181 | 8.6 | 11 | 2.5 |
| Participant care setting | ||||||
| Sexual health services | 1229 | 48.3 | 1003 | 47.8 | 226 | 50.9 |
| Genera Practice | 863 | 33.9 | 729 | 34.7 | 134 | 30.2 |
| Hospital/Tertiary referral settings | 452 | 17.8 | 368 | 17.5 | 84 | 18.9 |
| Duration of HIV (years), median (IQR) | 14.7 | 8.5 to 21.6 | 13.9 | 8.1 to 20.8 | 17.2 | 11.8 to 23.6 |
| Duration of ART (years), median (IQR) | 11.3 | 6.6 to 17.5 | 10.6 | 6.3 to 17.1 | 13.4 | 8.9 to 19.5 |
Abbreviations: ART, antiretroviral therapy; MSM, male to male sex; VL, viral load, IQR, interquartile range; NRTI, nucleoside/nucleotide reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; INSTI, integrase strand transfer inhibitor.